AGGRESSIVE NON-HODGKIN LYMPHOMA
Clinical trials for AGGRESSIVE NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new AGGRESSIVE NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple attack on lymphoma: freeze, vaccinate, and boost immunity
Disease control CompletedThis study tested a new combination treatment for people with non-Hodgkin lymphoma that had come back. The approach used three steps: first, freezing the tumor to kill cancer cells; second, injecting a personalized vaccine made from the patient's own immune cells; and third, givi…
Matched conditions: AGGRESSIVE NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New drug combo may reduce transplant complications in blood cancer patients
Disease control CompletedThis study tested different combinations of immune-suppressing drugs to prevent graft-versus-host disease (GVHD) in 174 patients with blood cancers who received a stem cell transplant from an unrelated donor. The goal was to find the most effective approach to reduce severe GVHD,…
Matched conditions: AGGRESSIVE NON-HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New hope for Tough-to-Treat lymphoma patients in clinical trial
Disease control CompletedThis study tested a four-drug combination including pixantrone for adults with aggressive non-Hodgkin lymphoma that had returned or not responded to previous treatments. The main goal was to see if the treatment could shrink or eliminate the cancer, as measured by PET scans. Rese…
Matched conditions: AGGRESSIVE NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Apr 06, 2026 14:14 UTC